Brief: Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic Hypoparathyroidism
12/06/2026 12:03
BRIEF-Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic Hypoparathyroidism June 12 (Reuters) - MBX Biosciences Inc MBX.O:
MBX BIOSCIENCES ANNOUNCES ONE-YEAR DATA DEMONSTRATING SUSTAINED BENEFIT OF ONCE-WEEKLY CANVUPARATIDE AS A POTENTIAL PTH REPLACEMENT THERAPY IN CHRONIC HYPOPARATHYROIDISM
MBX BIOSCIENCES - CANVUPARATIDE WELL TOLERATED WITH NO NEW SAFETY SIGNALS DURING ONE-YEAR OLE
MBX BIOSCIENCES - RESPONDER RATE 57% AT ONE YEAR OLE, 63% AT 12 WEEKS PHASE 2 AVAIL TRIAL
MBX BIOSCIENCES - PHASE 3 PIVOTAL TRIAL FOR CANVUPARATIDE ON TRACK TO INITIATE IN Q3 2026
MBX BIOSCIENCES - 90% OF PATIENTS IN OLE REMAINED IN STUDY AT ONE YEAR
Source text: ID:nGNX68yTP9
Further company coverage: MBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MBX Biosciences
See all newsU.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
MBX Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: MBX Biosciences Announces Executive Leadership Transition To Support The Company’S Next Phase Of Growth
MBX Biosciences falls after executive shakeup
U.S. STOCKS ON THE MOVE-SpaceX, Tesla, Woodside Energy Group